Tribe Capital Markets Resigns from Tribe Capital Growth Corp I (ATVC) Sponsor
by Nicholas Alan Clayton on 2022-06-07 at 11:39am

Tribe Capital I (NASDAQ:ATVC) announced in an 8-K this morning that Tribe Capital Markets has resigned from its sponsor and will effectively transfer management of it to Arrow Multi Asset Fund. However, a reason for the change was not provided.

The move is expected to be followed by a management shakeup with Tribe-connected officers including the SPAC’s CEO, CFO and secretary expected to depart. But existing Tribe I Vice President Sumit Mehta and Director Rohit Nanani also serve as executives at Arrow Capital, and therefore may be more likely to stick around.

In addition to contributing Mehta and Nanani to its management, Arrow Capital committed at the time of Tribe I’s IPO to fund up to 30% of the PIPE in any business combination that resulted.

There have been rumblings of SPAC sponsors seeking to sell their vehicles to new teams, but insurance and other complications have stood in the way. Officially, the parties have not yet given an explanation for the changes, but Tribe I initially listed in March 2021 and still has until March 2023 to complete a transaction. This is still an enviable amount of time given that roughly one in six SPACs still searching for a deal have less than six months left. Additionally, Tribe I is a 1/4 warrant structure and IPO’d with 100% in trust, or $10.00 day-one.  Both attractive terms compared to the current market.

Tribe Capital Growth Corp II, this team’s intended second SPAC that had never made it to IPO, had been in registration since March of 2021, but was recently declared abandoned by the SEC.

Nonetheless, the sponsor transition is also likely to see a change in focus for the SPAC, despite Arrow already having a presence before the changes. Tribe Capital is a Silicon Valley-based technology investor with about $540 million under management that uses a quantitative transaction data to hone in on its target list. Among the firm’s most prominent portfolio investments are stakes in crypto exchanges Kraken, FTX and DCC as well as a number of consumer fintech companies.

Arrow, meanwhile, is a boutique asset manager and investment advisor with offices in Dubai and Mauritius. It has primarily focused on the Gulf region to date but is currently expanding into Southeast Asia.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved